We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.'s share was trading at $2.30 as of December 1st.
[caption id="attachment_522182" align="aligncenter" width="750"]ImmunityBio (IBRX) is positioning itself at the forefront of one of the most pressing medical challenges—widespread immune exhaustion and lymphopenia, where reduced lymphocyte counts weaken the...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.